This patent application appeared to have been abandoned through lack of timely action, but a petition to extend Examination was GRANTED on 17 May. The failure to respond was deemed to be inadvertent.
This is a significant development, imo. The Examiner had contended that combining NOX66 with chemotherapy would have been obvious, but Noxopharm's attorney responded that the claim was for the combination of NOX66 plus sub-therapeutic doses of chemotherapy; and provided proof that the combination was effective. There is no prior art that suggests the use of sub-therapeutic doses of chemo.
Looking good for Allowance, in my view.
Add to My Watchlist
What is My Watchlist?
